98%
921
2 minutes
20
Post-traumatic stress symptoms (PTSS) have emerged as a prominent psychological consequence of the coronavirus disease 2019 (COVID-19) pandemic. Although early-stage fatigue is a known risk factor for developing PTSS, neural mechanisms linking fatigue and PTSS after COVID-19 infection remain unclear. In this study, we investigate whether dysfunctional fatigue-related brain functional connectivity during the acute phase is associated with PTSS in individuals with COVID-19 at 3-month follow-up. This prospective, longitudinal study enrolled 153 individuals with COVID-19 during the acute phase (<28 days post-infection, baseline), of whom 106 completed follow-up assessments at 3 months post-infection. All participants underwent T1-weighted three-dimensional brain volume and resting-state functional magnetic resonance imaging (MRI) scans at baseline and neuropsychiatric assessments at both baseline and follow-up. Complete MRI and neuropsychiatric assessment data of 34 healthy controls (HCs) were also included at baseline. Brain functional networks of all the participants were analyzed. At baseline, individuals with COVID-19 exhibited lower normalized characteristic path length and higher nodal efficiency in the right inferior frontal gyrus (IFG.R) (P < 0.05), compared to HCs. These abnormal brain topological metrics were associated with fatigue and PTSS scores (P < 0.05). Mediation analysis revealed that acute-phase physical fatigue fully mediated the relationship between baseline normalized characteristic path length and chronic hyperarousal symptom. Our results confirm that disrupted global normalized characteristic path length occurs in individuals with COVID-19 during the acute phase, and crucially, demonstrate that fatigue-related functional connectivity dysfunction is associated with the severity of PTSS in the chronic phase.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neuroscience.2025.07.038 | DOI Listing |
PLoS One
September 2025
Department of Information Technology, Uppsala University, Uppsala, Sweden.
For effective treatment of bacterial infections, it is essential to identify the species causing the infection as early as possible. Current methods typically require hours of overnight culturing of a bacterial sample and a larger quantity of cells to function effectively. This study uses one-hour phase-contrast time-lapses of single-cell bacterial growth collected from microfluidic chip traps, also known as a "mother machine".
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
September 2025
Doctorado en Genética Humana, Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Jalisco, México.
The objective of this study was to evaluate the concentration and integrity index of circulating cell-free DNA (ccf-DNA) as biomarkers for the detection and monitoring of minimal residual disease (MRD) in pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL). Comparison with a validated methodology for the quantification of monoclonal rearrangements of the IGH gene was made. Peripheral blood and bone marrow samples were collected from 10 pediatric patients with B-ALL at diagnosis, remission, and maintenance phases.
View Article and Find Full Text PDFmSphere
September 2025
Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
The ferret model is widely used to study influenza A viruses (IAVs) isolated from multiple avian and mammalian species, as IAVs typically replicate in the respiratory tract of ferrets without the need for prior host adaptation. During standard IAV risk assessments, tissues are routinely collected from ferrets at a fixed time point post-inoculation to assess the capacity for systemic spread. Here, we describe a data set of virus titers in tissues collected from both respiratory tract and extrapulmonary sites 3 days post-inoculation from over 300 ferrets inoculated with more than 100 unique IAVs (inclusive of H1, H2, H3, H5, H7, and H9 IAV subtypes, both mammalian and zoonotic origin).
View Article and Find Full Text PDFBlood Neoplasia
November 2025
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
Chronic myelomonocytic leukemia (CMML) is an aggressive hematologic neoplasm characterized by an expansion of CD123 monocytes and plasmacytoid dendritic cells (pDCs). pDC bone marrow clusters in CMML have been associated with higher rates of acute myeloid leukemia transformation. We evaluated tagraxofusp, a CD123-targeted therapy, in a phase 1/2 trial for patients with CMML.
View Article and Find Full Text PDFBlood Neoplasia
November 2025
The University of Texas MD Anderson Cancer Center, Houston, TX.
IO-202 is a humanized immunoglobulin G1 monoclonal antibody with high affinity and specificity for leukocyte immunoglobulin-like receptor B4 (LILRB4; ILT3), which is predominantly expressed in monocytes and monocytic blasts. IO-202 induces antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis in vitro and in patients with leukemia. Herein, we present the phase 1a dose escalation data of IO-202 as monotherapy and in combination with azacitidine (AZA) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and R/R chronic myelomonocytic leukemia (CMML), and the phase 1b dose expansion data of IO-202 combined with AZA for the treatment of hypomethylating agent (HMA)-naïve CMML.
View Article and Find Full Text PDF